; (II) improve the quality of care without increasing spending; or (III) increase access to behavioral health and substance use services for individuals with opioid use disorders. (ii) The Chief Actuary of the Centers for Medicare & Medicaid Services certifies that the condition described in clause (i) or (iii) is met. (iii) The Secretary determines that such waiver would not deny or limit the coverage or provision of benefits under this title for individuals. (E) Treatment of originating site facility fee No facility fee shall be paid under paragraph (2)(B) to an originating site with respect to a telehealth service for which payment is made under this subsection by reason of a waiver under this paragraph if payment for such service would not be permitted under this subsection without such waiver. (F) Definitions For purposes of this paragraph: (i) Eligible beneficiary The term eligible beneficiary means an individual who— (I) is entitled to benefits under part A and enrolled for benefits under this part; (II) is not enrolled in a Medicare Advantage plan under part C; (III) has a diagnosis for an opioid use disorder; and (IV) meets such other criteria as the Secretary determines appropriate. (ii) Opioid agonist treatment practitioner The term opioid agonist treatment practitioner means a practitioner who— (I) is enrolled under section 1866(j); and (II) is authorized to prescribe or dispense opioid agonist treatment medication for maintenance or detoxification treatment pursuant to a waiver under section 303(g)(2) of the Controlled Substances Act. (G) Report Not later than 5 years after the date of the enactment of this paragraph, the Secretary shall submit to Congress a report on the impact of any waivers granted under this paragraph on— (i) any change in utilization rates for behavioral health services for opioid use disorders; (ii) any change in rates or average length of time of retention in treatment for opioid use disorders; (iii) any change in emergency department visits related to opioid overdoses